Next-Generation Biologics Market 2018-2028 - Visiongain Report

LONDON, March 16, 2018 /PRNewswire/ --

Revenue Forecasts and R&D Trends for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant Coagulation Factors and Regenerative Medicine

     (Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg )

Report Details  

Next Generation Biologics Market Report 2018-2028: Forecasts by Market and Segments
• Do you need definitive Next Generation Biologics market data?
• Do you want to understand clear demarcation between next generation biologics and traditional biologics?
• Next Generation Biologics and sub-segment market analysis?
• Key drivers and constrains accompanied by this market?
• Clear leaders and lagers?
• Next wave of blockbusters and drivers impacting them?

Read on to discover how this definitive report can transform your own research and save you time.
The introduction of new pipeline drugs in Next generation biologics, has led visiongain to publish this timey report. The Next generation biologics market is expected to flourish in the next few years because of emergence of new phase III as well as marketed candidates which are going change the course of the market. Not only new candidates, but the technology (drug delivery as well as the mechanism of action) are novel which make the report a worth find and insightful.

Report highlights 

• 140 quantitative tables, charts, and graphs 

• Analysis of key players in Next generation biologics Market
• Abbvie
• Roche/ Genentech
• Amgen
• GSK
• Eli Lilly
• Sanofi Aventis
• Novo Nordisk
• Seattle Genetics

• Global next generation biologics market outlook and analysis from 2018-2028

• Regional Next generation biologics market forecasts from 2018-2028
• US forecast 2018-2028,
• Japan forecast 2018-2028
• India forecast 2018-2028
• Germany forecast 2018-2028
• UK forecast 2018-2028
• France forecast 2018-2028
• Italy forecast 2018-2028
• Spain forecast 2018-2028
• China forecast 2018-2028

• Key questions answered
• What does the future hold for the next generation biologics?
• Where should you target your business strategy?
• Which applications should you focus upon?
• Which disruptive technologies should you invest in?
• Which companies should you form strategic alliances with?
• Which company is likely to success and why?
• What business models should you adopt?
• What industry trends should you be aware of?

• Target audience
• Leading Pharmaceutical companies
• Suppliers
• Contractors
• Technologists
• R&D staff
• Consultants
• Analysts
• CEO's
• CIO's
• COO's
• Business development managers
• Investors
• Governments
• Agencies
• Industry organisations
• Banks

To request a report overview of this report please email Sara Peerun at sara.peerun@visiongain.com or call Tel: +44-(0)-20-7336-6100

Or click on: https://www.visiongain.com/Report/2148/Next-Generation-Biologics-Market-2018-2028

Companies Mentioned in the Report 

3SBio

Aastrom Biosciences (now Vericel Corporation)

AbbVie

Abcam

Ablynx

ADC Therapeutics

Adnexus (part of Bristol-Myers Squibb)

Adocia

Advanced Cell Technology (now Ocata Therapeutics)

Advantagene

Affibody

Agensys (now part of Astellas Pharma)

Alcon (part of Novartis)

Alexion Pharmaceuticals

Alfacell (now Tamir Biotechnology)

Alkermes

Allergan

Allozyne

Ambrx

Amgen

AMRI

AnGes

Applied Genetic Technologies (AGTC)

Ark Therapeutics

Astellas Pharma

AstraZeneca

Athersys

Avita Medical

Baxter International

Bayer Healthcare

Belrose Pharma

Benda Pharmaceutical

Biocad

BioCancell Therapeutics

Biocon

Biodel

Biogen Idec

Bioheart

BioMarin Pharmaceutical

Biopartners (part of Bioton)

Biotest Pharmaceuticals

Bioton

BioVex Group (part of Amgen)

BioWa (part of Kyowa Hakko Kirin)

bluebird bio

Boehringer Ingelheim

BrainStorm Cell Therapeutics

Bristol-Myers Squibb

Capricor Therapeutics

Cardio3 BioSciences

Cardium Therapeutics

Catalent Pharma Solutions

Celgene

Celladon

CellCoTec

Celldex Therapeutics

Cellerant Therapeutics

Cellular Dynamics International (CDI)

Cephalon (part of Teva)

CEPiA (part of Sanofi)

Ceregene

Chatham Therapeutics

Chiesi Farmaceutici

Chugai (part of Roche)

Civitas Therapeutics

Clayton Biotechnologies

Cold Genesys

Concortis

Covagen

Crescendo Biologics

Critical Pharmaceuticals

CSL Behring

CytoMedix

Cytori Therapeutics

Dance Biopharm

Delenex Therapeutics

Depuy Mitek (part of J&J)

Diabetology

Diasome Pharmaceuticals

Dr. Reddy's Laboratories

Dyax

Eddingpharm

EGEN

Eisai

Elan Pharmaceuticals (now part of Perrigo Company)

Eli Lilly

Emisphere

Enzon Pharmaceuticals

EnzymeRx

Epitomics (part of Abcam)

ESBATech (part of Novartis)

Flamel Technologies

Fresenius Biotech (now named Neovii Biotech, part of Neopharm)

Fuji Pharma

Fujifilm Diosynth Biotechnologies

Gamida Cell

Genentech (part of Roche)

Generex Biotechnology

Genmab

Genzyme (part of Sanofi)

Geron

GlaxoSmithKline (GSK)

GlycoExpress

Glycotope

Halozyme Therapeutics

Hanmi Pharmaceutical

Health Canada

Hikma Pharmaceuticals

Histogenics

Humacyte

Human Stem Cells Institute (HSCI)

Igenica

ImmunoGen

Immunomedics

Innovent Biologics

Integra LifeSciences

Introgen Therapeutics

Jain Foundation

JCR Pharmaceuticals

Johnson & Johnson (J&J)

Juventas Therapeutics

Karolinska Institute

Kyowa Hakko Kirin

LG Life Sciences

LifeCell

Lonza

Loyola University

MacroGenics

MannKind

MedImmune (part of AstraZeneca)

Merck & Co.

Merck KGaA

Merck Serono

Merrimack Pharmaceuticals

Merrion Pharmaceuticals

Mersana Therapeutics

Mesoblast

Micromet (part of Amgen)

Millennium Pharmaceuticals

Mitsubishi Tanabe Pharma

Mochida Pharmaceutical

Molecular Partners

MorphoSys

Nektar Therapeutics

Neopharm Group

NeoStem

NeuralStem

Nippon Kayaku

Novartis

Novo Nordisk

Nuron Biotech

NuVasive

Ocata Therapeutics (formerly Advanced Cell Technology)

OncoSec Medical

OPKO Health

Oramed Pharmaceuticals

Organogenesis

Organovo

Orthofix

Osiris Therapeutics

PeriphaGen Holdings

Perrigo Company

Pfizer

Pieris

Piramal Group

Progenics Pharmaceuticals

Prolor Biotech (part of OPKO Health)

Rani Therapeutics

ratiopharm (part of Teva)

Redwood Bioscience

Regeneron Pharmaceuticals

Reliance Life Sciences

ReNeuron

RIKEN [Japan]

Roche

Roche Glycart (part of Roche)

SAFC

Sandoz (part of Novartis)

Sanofi

Seattle Genetics

Shanghai Sunway Biotech

Shenzhen SiBiono GeneTech (part of Benda)

Shreya Life Sciences

SironRX Therapeutics

Skye Orthobiologics

Sorrento Therapeutics

Sotex PharmFirm

Spark Therapeutics

Spectrum Pharmaceuticals

Spirogen (part of AstraZeneca)

Stelis Biopharmaceuticals (part of Strides Arcolab)

Stem CentRx

StemCells

Stempeutics Research

Strativa Pharmaceuticals

Strides Arcolab

Sutro Biopharma

Swedish Orphan Biovitrum (Sobi)

Symphogen

Synthon

Synthon Biopharmaceuticals BV (part of Synthon)

Takeda Pharmaceutical Company

Teva Pharmaceutical Industries

Thermalin Diabetes

TiGenix

TRION Pharma

UCB

UniQure

USV

VBL Therapeutics

Vericel Corporation

Versartis

viDA Therapeutics

Viventia Biotechnologies Inc

VX Pharma

Wyeth (part of Pfizer)

Xencor

Xeris Pharmaceuticals

Zydus Cadila

To see a report overview please email Sara Peerun on sara.peerun@visiongain.com